Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
AssigneeUniversity of Southern California
InventorsMichael Kahn, Jia-Ling Teo, Michael McMillan, Yi Zhao, Yongfeng Wu
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Southern California
InventorsMichael Kahn, Jia-Ling Teo, Michael McMillan, Yi Zhao, Yongfeng Wu
Estimating the term…
Provided are: methods for treating aging or an age-related condition, symptom or disease; methods for stimulating hair growth, regrowth or pigmentation (or preventing hair loss); methods for increasing the expression of an adenosine receptor in dermal cells (in combination with hair growth); methods for treating a condition or disease of the skin or at least one symptom thereof, including cosmetic treatment (e.g., wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, and loss of vibrance). The methods comprise administering a sufficient amount of a CBP/catenin (e.g., CBP/β-catenin) antagonist as disclosed, and particularly wherein administration is in an amount and manner sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions in relevant somatic stem cell population. In particular aspects, the CBP/catenin (e.g., CBP/β-catenin) antagonist comprises an alkyl and/or fatty acid ester derivative thereof as disclosed herein.
A method for treating aging or an age-related condition, symptom or disease, comprising:
A method for stimulating hair growth, regrowth or pigmentation, comprising administering to a subject in need thereof an amount of a CBP/catenin antagonist sufficient for stimulating at least one of hair growth, regrowth, and pigmentation.
A method for increasing the expression of an adenosine receptor in dermal cells, comprising administering to a subject in need thereof an amount of a CBP/catenin antagonist sufficient for increase the expression of an adenosine receptor in dermal cells, preferably dermal papilla cells.
A method for treating a condition or disease of the skin or at least one symptom thereof, comprising administering to a subject in need thereof an amount of a CBP/β-catenin antagonist sufficient for treating a condition or disease of the skin or at least one symptom thereof.
A method for cosmetically treating a condition of the skin or at least one symptom thereof, comprising administering to a subject in need thereof an amount of a CBP/catenin antagonist sufficient for cosmetically treating a condition of the skin or at least one symptom thereof.
Dependencies are inferred from the claim text.